{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:55:43Z","timestamp":1794603343221,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073382"],"award-info":[{"award-number":["82073382"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Fundamental Research Funds for the Central Universities","award":["0214-14380506"],"award-info":[{"award-number":["0214-14380506"]}]},{"name":"The Nanjing Health Technology Development General Project","award":["YKK23084"],"award-info":[{"award-number":["YKK23084"]}]},{"name":"Jiangsu Provincial Natural Science Foundation Youth Project","award":["BK20230151"],"award-info":[{"award-number":["BK20230151"]}]},{"name":"Beijing Xisike Clinical Oncology Research Founadation","award":["Y-Young2023-019"],"award-info":[{"award-number":["Y-Young2023-019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The CLDN18-ARHGAP fusion gene is an oncogenic driver newly discovered in gastric cancer. It was detected in 9% (8\/87) of gastric cancer patients in our center. An immunogenic peptide specifically targeting CLDN18-ARHGAP fusion gene was generated to induce neoantigen-reactive T cells, which was proved to have specific and robust anti-tumor capacity both in in vitro coculture models and in vivo xenograft gastric cancer models. Apart from the immunogenic potential, CLDN18-ARHGAP fusion gene was also found to contribute to immune suppression by inducing a regulatory T (Treg) cell-enriched microenvironment. Mechanistically, gastric cancer cells with CLDN18-ARHGAP fusion activate PI3K\/AKT-mTOR-FAS signaling, which enhances free fatty acid production of gastric cancer cells to favor the survival of Treg cells. Furthermore, PI3K inhibition could effectively reverse Treg cells upregulation to enhance anti-tumor cytotoxicity of neoantigen-reactive T cells in vitro and reduce tumor growth in the xenograft gastric cancer model. Our study identified the CLDN18-ARHGAP fusion gene as a critical source of immunogenic neoepitopes, a key regulator of the tumor immune microenvironment, and immunotherapeutic applications specific to this oncogenic fusion.<\/jats:p>","DOI":"10.1038\/s44321-024-00120-3","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T14:03:34Z","timestamp":1724162614000},"page":"2170-2187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Yue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9825-3983","authenticated-orcid":false,"given":"Tao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueru","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8745-3288","authenticated-orcid":false,"given":"Keying","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-8878","authenticated-orcid":false,"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"120_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, Osokin N, Kozlov I, Frenkel F, Gancharova O et al (2021) Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39:845\u2013865.e7","journal-title":"Cancer Cell"},{"key":"120_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"120_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird P, Curtis C, Shen H et al (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202\u2013209","journal-title":"Nature"},{"key":"120_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA (2021) Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 18:215\u2013229","journal-title":"Nat Rev Clin Oncol"},{"key":"120_CR5","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1172\/JCI99538","volume":"129","author":"F Chen","year":"2019","unstructured":"Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y et al (2019) Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Investig 129:2056\u20132070","journal-title":"J Clin Investig"},{"key":"120_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1073\/pnas.1422640112","volume":"112","author":"K Chen","year":"2015","unstructured":"Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H et al (2015) Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci USA 112:1107\u20131112","journal-title":"Proc Natl Acad Sci USA"},{"key":"120_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","volume":"19","author":"T Chen","year":"2021","unstructured":"Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, Dong L, Zhang Z, Yu C, Sun Y et al (2021) The Genome Sequence Archive Family: toward explosive data growth and diverse data types. Genomics Proteom Bioinforma 19:578\u2013583","journal-title":"Genomics Proteom Bioinforma"},{"key":"120_CR8","doi-asserted-by":"publisher","first-page":"D27","DOI":"10.1093\/nar\/gkab951","volume":"50","author":"CNCB-NGDC Members and Partners","year":"2022","unstructured":"CNCB-NGDC Members and Partners (2022) Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022. Nucleic Acids Res 50:D27\u2013D38","journal-title":"Nucleic Acids Res"},{"key":"120_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K et al (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21:449\u2013456","journal-title":"Nat Med"},{"key":"120_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbcan.2017.12.003","volume":"1869","author":"X Dai","year":"2018","unstructured":"Dai X, Theobard R, Cheng H, Xing M, Zhang J (2018) Fusion genes: a promising tool combating against cancer. Biochim Biophys Acta Rev Cancer 1869:149\u2013160","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"120_CR11","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808\u20134817","journal-title":"Blood"},{"key":"120_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18:197\u2013218","journal-title":"Nat Rev Drug Discov"},{"key":"120_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L et al (2018) Driver fusions and their implications in the development and treatment of human cancers. Cell Rep 23:227\u2013238","journal-title":"Cell Rep"},{"key":"120_CR14","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1073\/pnas.1617709114","volume":"114","author":"AM Gouw","year":"2017","unstructured":"Gouw AM, Eberlin LS, Margulis K, Sullivan DK, Toal GG, Tong L, Zare RN, Felsher DW (2017) Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci USA 114:4300\u20134305","journal-title":"Proc Natl Acad Sci USA"},{"key":"120_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002279","volume":"9","author":"S Isoyama","year":"2021","unstructured":"Isoyama S, Mori S, Sugiyama D, Kojima Y, Tada Y, Shitara K, Hinohara K, Dan S, Nishikawa H (2021) Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. J Immunother Cancer 9:e002279","journal-title":"J Immunother Cancer"},{"key":"120_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340","journal-title":"Lancet"},{"key":"120_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT et al (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22:851\u2013860","journal-title":"Nat Med"},{"key":"120_CR18","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA: Cancer J Clin 71:264\u2013279","journal-title":"CA: Cancer J Clin"},{"key":"120_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20:25\u201339","journal-title":"Nat Rev Immunol"},{"key":"120_CR20","doi-asserted-by":"publisher","first-page":"7596","DOI":"10.1158\/1078-0432.CCR-17-0618","volume":"23","author":"JL Kalina","year":"2017","unstructured":"Kalina JL, Neilson DS, Lin Y-Y, Hamilton PT, Comber AP, Loy EMH, Sahinalp SC, Collins CC, Hach F, Lum JJ (2017) Mutational analysis of gene fusions predicts novel MHC class I\u2013restricted T-cell epitopes and immune signatures in a subset of prostate cancer. Clin Cancer Res 23:7596\u20137607","journal-title":"Clin Cancer Res"},{"key":"120_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P et al (2016) PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539:437\u2013442","journal-title":"Nature"},{"key":"120_CR22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471","journal-title":"Lancet"},{"key":"120_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24:1449\u20131458","journal-title":"Nat Med"},{"key":"120_CR24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.cell.2020.05.053","volume":"181","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Karali E, Tripp A, Valle A, Inglese P, Perry NJS, Magee DJ, Anjomani Virmouni S, Elder GA, Tyson AL et al (2020) Metabolic fingerprinting links oncogenic PIK3CA with enhanced arachidonic acid-derived eicosanoids. Cell 181:1596\u20131611.e27","journal-title":"Cell"},{"key":"120_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","volume":"53","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M et al (2020) An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity 53:187\u2013203","journal-title":"Immunity"},{"key":"120_CR26","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang KK, Tay ST et al (2022) Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov 12:670\u2013691","journal-title":"Cancer Discov"},{"key":"120_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/his.13383","volume":"72","author":"CH Kwon","year":"2018","unstructured":"Kwon CH, Kim YK, Lee S, Kim A, Park HJ, Choi Y, Won YJ, Park DY, Lauwers GY (2018) Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology 72:556\u2013568","journal-title":"Histopathology"},{"key":"120_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA (2020) Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell 38:454\u2013472","journal-title":"Cancer Cell"},{"key":"120_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K et al (2023) Challenges in neoantigen-directed therapeutics. Cancer Cell 41:15\u201340","journal-title":"Cancer Cell"},{"key":"120_CR30","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1158\/1078-0432.CCR-07-4065","volume":"14","author":"CL Mackall","year":"2008","unstructured":"Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M et al (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14:4850\u20134858","journal-title":"Clin Cancer Res"},{"key":"120_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-018-0868-0","volume":"22","author":"C Mariette","year":"2019","unstructured":"Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G (2019) Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer 22:1\u20139","journal-title":"Gastric Cancer"},{"key":"120_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrc3947","volume":"15","author":"F Mertens","year":"2015","unstructured":"Mertens F, Johansson B, Fioretos T, Mitelman F (2015) The emerging complexity of gene fusions in cancer. Nat Rev Cancer 15:371\u2013381","journal-title":"Nat Rev Cancer"},{"key":"120_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05556-x","volume":"7","author":"ME Muroski","year":"2017","unstructured":"Muroski ME, Miska J, Chang AL, Zhang P, Rashidi A, Moore H, Lopez-Rosas A, Han Y, Lesniak MS (2017) Fatty acid uptake in T cell subsets using a quantum dot fatty acid conjugate. Sci Rep 7:5790","journal-title":"Sci Rep"},{"key":"120_CR34","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","volume":"6","author":"K Okkenhaug","year":"2016","unstructured":"Okkenhaug K, Graupera M, Vanhaesebroeck B (2016) Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov 6:1090\u20131105","journal-title":"Cancer Discov"},{"key":"120_CR35","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","volume":"21","author":"K Ota","year":"2015","unstructured":"Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S et al (2015) Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 21:4014\u20134021","journal-title":"Clin Cancer Res"},{"key":"120_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB (2022) The hallmarks of cancer metabolism: still emerging. Cell Metab 34:355\u2013377","journal-title":"Cell Metab"},{"key":"120_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X et al (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6:202\u2013216","journal-title":"Cancer Discov"},{"key":"120_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","volume":"95","author":"J Pinilla-Ibarz","year":"2000","unstructured":"Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95:1781\u20131787","journal-title":"Blood"},{"key":"120_CR39","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y et al (2022) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28:1189\u20131198","journal-title":"Nat Med"},{"key":"120_CR40","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","volume":"28","author":"P Rutkowski","year":"2010","unstructured":"Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D et al (2010) Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 28:1772\u20131779","journal-title":"J Clin Oncol"},{"key":"120_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04907-0","volume":"9","author":"Y Shu","year":"2018","unstructured":"Shu Y, Zhang W, Hou Q, Zhao L, Zhang S, Zhou J, Song X, Zhang Y, Jiang D, Chen X et al (2018) Prognostic significance of frequent CLDN18-ARHGAP26\/6 fusion in gastric signet-ring cell cancer. Nat Commun 9:2447","journal-title":"Nat Commun"},{"key":"120_CR42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS (2019) Alternative tumour-specific antigens. Nat Rev Cancer 19:465\u2013478","journal-title":"Nat Rev Cancer"},{"key":"120_CR43","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396:635\u2013648","journal-title":"Lancet"},{"key":"120_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523:231\u2013235","journal-title":"Nature"},{"key":"120_CR45","doi-asserted-by":"publisher","first-page":"eaav3937","DOI":"10.1126\/sciimmunol.aav3937","volume":"5","author":"E Sugiyama","year":"2020","unstructured":"Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E (2020a) Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol 5:eaav3937","journal-title":"Sci Immunol"},{"key":"120_CR46","doi-asserted-by":"publisher","first-page":"eaav3937","DOI":"10.1126\/sciimmunol.aav3937","volume":"5","author":"E Sugiyama","year":"2020","unstructured":"Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K et al (2020b) Blockade of EGFR improves responsiveness to PD-1 blockade in -mutated non-small cell lung cancer. Sci Immunol 5:eaav3937","journal-title":"Sci Immunol"},{"key":"120_CR47","doi-asserted-by":"publisher","first-page":"e003093","DOI":"10.1136\/jitc-2021-003093","volume":"9","author":"P Sun","year":"2021","unstructured":"Sun P, Zhang X, Wang RJ, Ma QY, Xu L, Wang Y, Liao HP, Wang HL, Hu LD, Kong X et al (2021) PI3Kalpha inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8(+)T cells and promoting fatty acid metabolism. J Immunother Cancer 9:e003093","journal-title":"J Immunother Cancer"},{"key":"120_CR48","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin 71:209\u2013249","journal-title":"CA: Cancer J Clin"},{"key":"120_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A (2022) Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol 80:1\u201317","journal-title":"Semin Cancer Biol"},{"key":"120_CR50","doi-asserted-by":"publisher","first-page":"94ra72","DOI":"10.1126\/scitranslmed.3001970","volume":"3","author":"SA Tomlins","year":"2011","unstructured":"Tomlins SA, Aubin SMJ, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A et al (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3:94ra72","journal-title":"Sci Transl Med"},{"key":"120_CR51","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM et al (2016) T-cell transfer therapy targeting mutant KRAS in cancer. New Engl J Med 375:2255\u20132262","journal-title":"New Engl J Med"},{"key":"120_CR52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641\u2013645","journal-title":"Science"},{"key":"120_CR53","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M et al (2017) Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 18:1009\u20131021","journal-title":"Lancet Oncol"},{"key":"120_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41571-022-00633-1","volume":"19","author":"N Vasan","year":"2022","unstructured":"Vasan N, Cantley LC (2022) At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol 19:471\u2013485","journal-title":"Nat Rev Clin Oncol"},{"key":"120_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5675-4","volume":"19","author":"AD Wagner","year":"2019","unstructured":"Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U et al (2019) EORTC-1203-GITCG\u2014the \u201cINNOVATION\u201d-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 19:494","journal-title":"BMC Cancer"},{"key":"120_CR56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, Mohmood SR, Fern\u00e1ndez-Garc\u00eda J, Tsai C-H, Schulze I et al (2020) CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol 21:298\u2013308","journal-title":"Nat Immunol"},{"key":"120_CR57","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ng.2983","volume":"46","author":"K Wang","year":"2014","unstructured":"Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S et al (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46:573\u2013582","journal-title":"Nat Genet"},{"key":"120_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2021.02.023","volume":"506","author":"Y Wang","year":"2021","unstructured":"Wang Y, Shi T, Song X, Liu B, Wei J (2021) Gene fusion neoantigens: emerging targets for cancer immunotherapy. Cancer Lett 506:45\u201354","journal-title":"Cancer Lett"},{"key":"120_CR59","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A, Sakaguchi S (2019) Human FOXP3 regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity 50:302\u2013316","journal-title":"Immunity"},{"key":"120_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, Yi P, Tang L, Pan Q, Rao S et al (2021) The cancer metabolic reprogramming and immune response. Mol Cancer 20:28","journal-title":"Mol Cancer"},{"key":"120_CR61","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D (2021) Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 221:107753","journal-title":"Pharmacol Ther"},{"key":"120_CR62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan Y, Huang L, Liu Y, Yi M, Chu Q, Jiao D, Wu K (2022) Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol 15:104","journal-title":"J Hematol Oncol"},{"key":"120_CR63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","volume":"25","author":"W Yang","year":"2019","unstructured":"Yang W, Lee K-W, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L et al (2019) Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med 25:767\u2013775","journal-title":"Nat Med"},{"key":"120_CR64","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.celrep.2015.06.020","volume":"12","author":"F Yao","year":"2015","unstructured":"Yao F, Kausalya JP, Sia YY, Teo ASM, Lee WH, Ong AGM, Zhang Z, Tan JHJ, Li G, Bertrand D et al (2015) Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep 12:272\u2013285","journal-title":"Cell Rep"},{"key":"120_CR65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Johnson 3rd BA, Lutz ER, Laheru DA, Jaffee EM (2017) Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17:209\u2013222","journal-title":"Nat Rev Cancer"},{"key":"120_CR66","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","volume":"31","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A et al (2017) A pan-cancer proteogenomic atlas of PI3K\/AKT\/mTOR pathway alterations. Cancer Cell 31:820\u2013832.e3","journal-title":"Cancer Cell"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00120-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:48:54Z","timestamp":1779065334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00120-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,12]]}},"alternative-id":["120"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00120-3","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}